Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle

Acta Myologica

Volumn 26, Issue 1, 2007, Pages 61-63

  Vorgerd, Matthias ^a   Zange, J ^b,c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b GERMAN AEROSPACE CENTER DLR   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Creatine supplementation; Ketogenic diet; McArdle disease

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE; CREATINE PHOSPHATE; GLYCOGEN; GLYCOGEN PHOSPHORYLASE;

ARTICLE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG MEGADOSE; ENERGY METABOLISM; GENETIC DISORDER; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; KETOGENIC DIET; LEG MUSCLE; LOW DRUG DOSE; MUSCLE FUNCTION; MUSCLE METABOLISM; MYOPATHY; OUTCOME ASSESSMENT; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; SKELETAL MUSCLE; TRAINING;

CREATINE; DIETARY SUPPLEMENTS; GLYCOGEN STORAGE DISEASE TYPE V; HUMANS; MUSCLE, SKELETAL; TREATMENT OUTCOME;

EID: 34548625973     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Argov Z, Bank WJ, Maris J, Chance B. Muscle energy metabolism in McArdle's syndrome by in vivo phosphorus magnetic resonance spectroscopy. Neurology 1987;37:1720-4.
2. Braakhekke JP, de Bruin MI, Stegeman DF, et al. The second wind phenomenon in McArdle's disease. Brain 1986;109:1087-101.
3. Duboc D, Jehenson P, Tran Dinh S, et al. Phosphorus NMR spectroscopy study of muscle enzyme deficiencies involving glycogenolysis and glycolysis. Neurology 1987;37:663-71.
4. Zange J, Grehl T, Disselhorst-Klug C, et al. Breakdown of adenine nucleotide pool in fatiguing skeletal muscle in McArdle's disease: a noninvasive 31P-MRS and EMG study. Muscle Nerve 2003;27:728-36.
5. Radda GK, Gadian DG, Ross BD. Energy metabolism and cellular pH in normal and pathological conditions. A new look through 31-phosphorus nuclear magnetic resonance. Ciba Found Symp 1982;87:36-57.
6. Vorgerd M, Grehl T, Jäger M, et al. Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Arch Neurol 2000;57:956-63.
7. Vorgerd M, Zange J, Kley R, et al. Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. Arch Neurol 2002;59:97-101.
8. Coakley JH, Wagenmakers AJ, Edwards RH. Relationship between ammonia, heart rate, and exertion in McArdle's disease. Am J Physiol 1992;262:167-72.
9. Sahlin K, Areskog NH, Haller RG, et al. Impaired oxidative metabolism increases adenine nucleotide breakdown in McArdle's disease. J Appl Physiol 1990;69:1231-5.
10. 31P nuclear magnetic resonance study. Mol Biol Med 1983;1:77-94.
11. Kley RA, Vorgerd M, Tarnopolsky M. Creatine for treating muscle disorders. Cochrane Neuromuscular Disease Group 2006;in press.
12. Willott CA, Young ME, Leighton B, et al. Creatine uptake in isolated soleus muscle: kinetics and dependence on sodium, but not on insulin. Acta Physiol Scand 1999;166:99-104.
13. Kornblum C, Schröder R, Müller K, et al. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study. Eur J Neurol 2005;12:300-9.
14. Schöls L, Zange J, Abele M, et al. L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm 2005;112:789-96.
15. Zange J, Kornblum C, Müller K, et al. Creatine supplementation results in elevated phosphocreatine/adenosine triphosphate (ATP) ratios in the calf muscle of athletes but not in patients with myopathies. Letter. Ann Neurol 2002;52:126-7.
16. Lemon PW. Dietary creatine supplementation and exercise performance: why inconsistent results? Can J Appl Physiol 2002;27:663-81.
17. Vandenberghe K, Van Hecke P, Van Leemputte M, Vanstapel F, Hespel P. Phosphocreatine resynthesis is not affected by creatine loading. Med Sci Sports Exerc 1999;31:236-42.
18. Tarnopolsky MA, Parshad A, Walzel B, Schlattner U, Wallimann T. Creatine transporter and mitochondrial creatine kinase protein content in myopathies. Muscle Nerve 2001;24:682-8.
19. Vorgerd M, Schols L, Hardt C, et al. Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromusc Disord 2000;10:430-5.
20. Felber S, Skladal D, Wyss M, et al. Oral creatine supplementation in Duchenne muscular dystrophy: a clinical and 31P magnetic resonance spectroscopy study. Neurol Res 2000;22:145-50.
21. Brudnak MA. Creatine: are the benefits worth the risk? Toxicol Lett 2004;150:123-30.
22. Juhn MS, Tarnopolsky M. Oral creatine supplementation and athletic performance: a critical review. Clin J Sport Med 1998;8:286-97.
23. Haller RG, Wyrick P, Taivassalo T, Vissing J. Aerobic conditioning: an effective therapy in McArdle's disease. Ann Neurol 2006;59:922-8.
24. Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med 2003;349:2503-9.
25. Busch V, Gempel K, Hack A, et al. Treatment of glycogenosis type V with ketogenic diet. Ann Neurol 2005;58:341.